AN AUDIT INTO THE CLASS-I INDICATIONS FOR AMBULATORY ECG MONITORING IN A SAMPLE OF ELDERLY POPULATION

2011 ◽  
Vol 22 ◽  
pp. S90
Author(s):  
Kamran Tariq ◽  
Shahirose Jessani ◽  
Edward Casswell ◽  
Farhad Huwez
Keyword(s):  
Elderly Population ◽  
Class I ◽  
Ecg Monitoring ◽  
Ambulatory Ecg ◽  
Ambulatory Ecg Monitoring

Loss of Efficacy during Long-Term Cifenline Therapy: Development of Antiarrhythmic Resistance?

1993 ◽  
Vol 27 (5) ◽  
pp. 550-554 ◽  
Author(s):  
Syed M. Mohiuddin ◽  
Tom T. Hee ◽  
Claire B. Hunter ◽  
Daniel E. Hilleman ◽  
Michael H. Sketch
Keyword(s):  
Class I ◽  
Antiarrhythmic Agents ◽  
Ecg Monitoring ◽  
Antiarrhythmic Drug Therapy ◽  
Ambulatory Ecg ◽  
Ambulatory Ecg Monitoring ◽  
Alternative Drug ◽  
Dose Ranging

OBJECTIVE: To describe the possible development of antiarrhythmic resistance to cifenline, an investigational Class I agent. METHODS: Forty patients with chronic ventricular premature depolarizations (VPDs) underwent dose-ranging studies with cifenline, an investigational Class I antiarrhythmic agent. Patients had a minimum of 30 VPDs/h detected by ambulatory electrocardiographic (ECG) monitoring over a 48-hour baseline placebo lead-in period. Twenty-two patients (55 percent) who initially responded received long-term cifenline therapy. Ambulatory ECG monitoring over 24 hours was repeated during active cifenline therapy at three-month intervals and during placebo reintroduction at six-month intervals. RESULTS: After an average follow-up of 28 months, VPD frequency during cifenline therapy was similar to that during initial baseline placebo therapy in 8 of the 22 patients (36 percent) who initially responded. Placebo reintroduction following cifenline failure showed a VPD frequency similar to that with active therapy. All patients had further cifenline dosage increases without success. Plasma cifenline concentrations increased in all patients and were in the high therapeutic range. All 8 patients were switched to other Class I antiarrhythmic agents with successful VPD suppression during treatment with the first alternative drug. CONCLUSIONS: We conclude that antiarrhythmic resistance occurred with cifenline in these patients as (1) initial efficacy was established for a minimum of two years, (2) VPD frequency was similar during cifenline therapy and placebo reintroduction, (3) cifenline therapy failure continued despite further dosage titration, and (4) alternative Class I antiarrhythmic therapy was successful in all patients. Repeat intermittent ambulatory ECG monitoring is necessary not only to assess the continued need for antiarrhythmic drug therapy, but also to establish continued long-term efficacy.

Ambulatory ECG Monitoring in Atrial Fibrillation Management

2013 ◽  
Vol 56 (2) ◽  
pp. 143-152 ◽  
Author(s):  
Spencer Z. Rosero ◽  
Valentina Kutyifa ◽  
Brian Olshansky ◽  
Wojciech Zareba
Keyword(s):  
Atrial Fibrillation ◽  
Ecg Monitoring ◽  
Ambulatory Ecg ◽  
Ambulatory Ecg Monitoring

Can Changes in S Wave Amplitude be Used to Detect Ischaemia during Ambulatory ECG Monitoring?

1986 ◽  
Vol 70 (s13) ◽  
pp. 1P-1P
Author(s):  
J.J. Glazier ◽  
S. Chierchia ◽  
A. Maseri
Keyword(s):  
Wave Amplitude ◽  
Ecg Monitoring ◽  
S Wave ◽  
Ambulatory Ecg ◽  
Ambulatory Ecg Monitoring

System for Continuous and Prolonged Ambulatory ECG Monitoring with Hosting and Visualization on the Cloud

2021 ◽  
Vol 10 (1) ◽  
pp. 57
Author(s):  
Daniel Cuevas-González ◽  
Juan Pablo García-Vázquez ◽  
Miguel Bravo-Zanoguera ◽  
Roberto López-Avitia ◽  
Marco A. Reyna ◽  
...  
Keyword(s):  
Health Care ◽  
Sampling Rate ◽  
Cloud Services ◽  
Ecg Signal ◽  
Ecg Monitoring ◽  
Ambulatory Ecg ◽  
Ambulatory Ecg Monitoring ◽  
Access Information ◽  
Electrocardiogram Ecg ◽  
Small File

In this paper, we propose investigating the ability to integrate a portable Electrocardiogram (ECG) device to commercial platforms to analyze and visualize information hosted in the cloud. Our ECG system based on the ADX8232 microchip was evaluated regarding its performance of recordings of a synthetic ECG signal for periods of 1, 2, 12, 24, and 36 h on six different cloud services to investigate whether it maintains reliable ECG records. Our results show that there are few cloud services capable of 24 h or longer ECG recordings. But some existing services are limited to small file sizes of less than 1,000,000 lines or 100 MB, or approximately 45 min of an ECG recording at a sampling rate of 360 Hz, making it difficult an extended time monitoring. Cloud platforms reveal some limitations of storage and visualization in order to provide support to health care specialists to access information related to a patient at any time.

Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study.

1989 ◽  
Vol 7 (4) ◽  
pp. 509-514 ◽  
Author(s):  
S Rezkalla ◽  
R A Kloner ◽  
J Ensley ◽  
M al-Sarraf ◽  
S Revels ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Cardiac Toxicity ◽  
Ecg Monitoring ◽  
Ecg Changes ◽  
Ambulatory Ecg ◽  
Ambulatory Ecg Monitoring ◽  
St Segment ◽  
Artery Disease ◽  
A Prospective Study

Although there have been anecdotal reports of cardiac toxicity associated with fluorouracil (5-FU) therapy, this phenomenon has not been studied in a systematic fashion. We prospectively performed continuous ambulatory ECG monitoring on 25 patients undergoing 5-FU infusion for treatment of solid tumors in order to assess the incidence of ischemic ST changes. Patients were monitored for 23 +/- 4 hours before 5-FU infusion, and 98 +/- 9 hours during 5-FU infusion. Anginal episodes were rare: only one patient had angina (during 5-FU infusion). However, asymptomatic ST changes (greater than or equal to 1 mm ST deviation) were common: six of 25 patients (24%) had ST changes before 5-FU infusion v 17 (68%) during 5-FU infusion (P less than .002). The incidence of ischemic episodes per patient per hour was 0.05 +/- 0.02 prior to 5-FU infusion v 0.13 +/- 0.03 during 5-FU infusion (P less than .001); the duration of ECG changes was 0.6 +/- 0.3 minutes per patient per hour before 5-FU v 1.9 +/- 0.5 minutes per patient per hour during 5-FU (P less than .01). ECG changes were more common among patients with known coronary artery disease. There were two cases of sudden death, both of which occurred at the end of the chemotherapy course. We conclude that 5-FU infusion is associated with a significant increase in silent ST segment deviation suggestive of ischemia, particularly among patients with coronary artery disease. The mechanism and clinical significance of these ECG changes remain to be determined.

Sign in / Sign up

Export Citation Format

Share Document